greeksoup/ stock research

Leidos Holdings, Inc.: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 3 November 2026: press release. Guidance figures: 2 raised, 1 lowered, 1 kept. The quarter’s numbers.

Key takeaways

  • Revenue rose on defense and air traffic demand: Revenue rose 4% to $4.63 billion. Management attributed growth to defense tech, air traffic management and intelligence mission support, plus the ENTRUST acquisition, offset by declines in managed health and federal civilian IT. Source
  • Net income and EPS both grew: Net income rose 12% to $413 million and diluted EPS rose 16% to $3.28. Non-GAAP diluted EPS was $3.62, up 19% from $3.05. Source
  • Health revenue fell 12%: Health revenue fell 12% to $1.07 billion and operating margin was 22.5% versus 26.8%. Management cited expected program shifts and reduced managed health volumes. Source
  • Bookings of $5.5 billion: Net bookings were $5.5 billion, a book-to-bill ratio of 1.2. Trailing-twelve-month book-to-bill was 1.1. Source
  • Backlog reached $49.6 billion: Backlog was $49.6 billion, of which $11.1 billion was funded. Total backlog rose 4% and funded backlog rose 22% year-over-year on a trailing basis. Source
  • Operating cash flow of $523 million: Operating cash flow was $523 million, a 128% conversion. Free cash flow was $476 million, a 105% conversion, against $711 million and $680 million a year earlier. Source
  • $556 million returned to holders: Shareholder returns were $556 million: $504 million of buybacks and $52 million of dividends. Nine-month repurchases were $819 million. Source
  • Altaris joint venture closed: On October 5, 2026, the company closed the agreement with Altaris and contributed its SES businesses to a new joint venture. The prior release referred to a joint venture with Analogic Corporation. Source

“Our sustained momentum reflects the strength of our focused team, united behind our NorthStar 2030 strategy and committed to delivering on our customers’ most critical missions.”

Chief Executive Officer Tom Bell

Guidance

AreaPeriodFigureAgainst last quarter
Revenues (B) Sourcefiscal year 2026$18.00 - $18.20Lowered from $18.20 - $18.40
Adjusted EBITDA margin Sourcefiscal year 2026Mid 13%Kept
Non-GAAP diluted EPS Sourcefiscal year 2026$12.50 - $12.70Raised from $12.20 - $12.50
Cash flows provided by operating activities (B) Sourcefiscal year 2026Approximately $1.90Raised from Approximately $1.85

What changed from last quarter

  • Guidance lowered: FY26 revenue guidance was lowered to $18.00 to $18.20 billion from $18.20 to $18.40 billion. Source
  • Guidance raised: FY26 non-GAAP diluted EPS guidance was raised to $12.50 to $12.70 from $12.20 to $12.50. Source
  • Guidance raised: FY26 operating cash flow guidance was raised to approximately $1.90 billion from approximately $1.85 billion. Source
  • New: The SES businesses were contributed to a joint venture with Altaris, closed October 5, 2026. Source
  • New: The quarterly dividend was declared at $0.45 per share, an increase of 4.7% over the prior quarter's amount. Source

Results and growth drivers

  • Revenue rose on defense and air traffic demand: Revenue rose 4% to $4.63 billion. Management attributed growth to defense tech, air traffic management and intelligence mission support, plus the ENTRUST acquisition, offset by declines in managed health and federal civilian IT. Source
  • Organic revenue growth was 0.6%: Excluding acquisition and divestiture revenue of $142 million, revenue was $4.49 billion, up 0.6% from $4.46 billion a year earlier. Source
  • Net income and EPS both grew: Net income rose 12% to $413 million and diluted EPS rose 16% to $3.28. Non-GAAP diluted EPS was $3.62, up 19% from $3.05. Source
  • Program performance and cost control cited: Management attributed profitability to improved program performance and disciplined cost management, with adjusted EBITDA up 5% to $644 million. Source

Segment results

  • Intelligence & Digital margin widened: Intelligence & Digital revenue rose 1% to $1.55 billion on recent awards. Operating margin was 11.1% versus 9.2%; non-GAAP operating margin was 11.5%. Source
  • Health revenue fell 12%: Health revenue fell 12% to $1.07 billion and operating margin was 22.5% versus 26.8%. Management cited expected program shifts and reduced managed health volumes. Source
  • Homeland grew 32% with ENTRUST: Homeland revenue rose 32% to $1.02 billion, including $142 million from ENTRUST. Non-GAAP operating margin was 11.3% versus 7.5%, reflecting a higher mix of commercial work. Source
  • Defense revenue rose 3%: Defense revenue rose 3% to $992 million, led by air defense, sensing and C5ISR demand. Operating margin was 8.7%; non-GAAP operating margin was 9.7% versus 9.8%. Source

“allowing us to enhance our 2026 guidance for the third consecutive quarter”

Chief Executive Officer Tom Bell

Awards and customer programs

  • Air Force and TSA awards headlined bookings: Key awards included a $717 million Air Force ACC A2 intelligence contract and a $672 million TSA security equipment deployment contract. Source
  • Army and CYBERCOM cyber awards: A $301 million Army defensive cyber follow-on and a five-year $160 million CYBERCOM award, described as Leidos' first cyber operations award with that command. Source
  • Missile defense sensing payloads: A $272 million Sierra Space award supplies infrared sensing payloads and onboard processing for 18 SDA missile-tracking satellites in Tranche 3. Source
  • Health and DHS EHR contracts: A $129 million CBP and ICE EHR blanket purchase agreement and a $318 million sole-source MHS GENESIS bridge contract extend federal health IT work. Source
  • Havoc Spear low-rate production: A $27 million special operations award covers low-rate production of the AGM-190A Havoc Spear, which management said has potential for broad deployment. Source

Costs, margins and tax

  • Cost of revenues rose with volume: Cost of revenues rose to $3.81 billion from $3.65 billion. Selling, general and administrative expenses fell to $262 million from $290 million. Source
  • Transaction costs excluded from non-GAAP: Net income and diluted EPS reflect $12 million in costs for recent strategic corporate transactions, which the company excluded from non-GAAP results. Source
  • Lower tax expense lifted earnings: Income tax expense was $69 million versus $115 million, reflecting a lower effective rate from a higher federal research tax credit and lower unrecognized tax benefits. Source
  • Net interest expense rose: Interest expense, net was $67 million in the quarter, compared with $51 million in the prior year quarter. Source

“Looking ahead, we’ll continue to execute our strategy with confidence, invest in differentiated capabilities, and deploy capital strategically to accelerate growth and create enduring value.”

Chief Executive Officer Tom Bell

Demand and order book

  • Bookings of $5.5 billion: Net bookings were $5.5 billion, a book-to-bill ratio of 1.2. Trailing-twelve-month book-to-bill was 1.1. Source
  • Backlog reached $49.6 billion: Backlog was $49.6 billion, of which $11.1 billion was funded. Total backlog rose 4% and funded backlog rose 22% year-over-year on a trailing basis. Source
  • Health backlog declined: Backlog by segment was Intelligence & Digital $18.2 billion, Defense $14.7 billion, Homeland $10.4 billion and Health $6.3 billion, down from $8.0 billion. Source

Cash flow and shareholder returns

  • Operating cash flow of $523 million: Operating cash flow was $523 million, a 128% conversion. Free cash flow was $476 million, a 105% conversion, against $711 million and $680 million a year earlier. Source
  • $556 million returned to holders: Shareholder returns were $556 million: $504 million of buybacks and $52 million of dividends. Nine-month repurchases were $819 million. Source
  • Dividend raised 4.7%: The Board declared a $0.45 cash dividend per share on October 30, 2026, an increase of 4.7% over the prior quarter's amount. Source
  • Cash and debt at quarter end: At October 2, 2026, cash and equivalents were $630 million and debt was $6.0 billion. Source

Portfolio changes and balance sheet

  • Altaris joint venture closed: On October 5, 2026, the company closed the agreement with Altaris and contributed its SES businesses to a new joint venture. The prior release referred to a joint venture with Analogic Corporation. Source
  • Assets held for sale recorded: Assets held for sale were $904 million and liabilities held for sale were $171 million at October 2, 2026, with none at fiscal year-end. Source
  • Goodwill and intangibles increased: Goodwill rose to $7,725 million from $6,342 million, and intangible assets rose to $879 million from $458 million since fiscal year-end. Source
  • Acquisition cash and Entrust backlog: Acquisitions used $2,338 million of cash in the nine months. Entrust carried $371 million of backlog at its March 27, 2026 acquisition date, within Homeland. Source

Strategy and investment

  • Strategy execution and capital deployment: Management said it will keep executing its strategy, invest in differentiated capabilities and deploy capital strategically to accelerate growth. Source
  • Autonomous AI in cyber operations: The Army cyber award uses the UpHold Effect Agentic SOC Automation platform, which relies on autonomous AI agents to compress threat response windows. Source
  • Air traffic position strengthened abroad: The UK NATS flight data processing award upgrades core software, which the company said strengthens its global position in next-generation air traffic management. Source

Coming up, as management said on 3 November 2026

  • Dividend payable December 31: The $0.45 cash dividend is payable December 31, 2026, to stockholders of record at the close of business on December 15, 2026. Source
  • Havoc Spear initial deliveries: Under the LRIP award, Leidos will deliver an initial 45 All Up Rounds for fielding in Air Force Special Operations Command. Source
  • ICE EHR expansion across DHS: Management described the ICE EHR award as a foundation for expansion across DHS components, building on the MHS GENESIS work. Source

Risks management discussed

  • Demand: Health revenue declines came from expected program shifts and reduced managed health volumes, which management said drove the quarter's Health results. Source
  • Operational: Recent strategic corporate transactions carried $12 million of costs in the quarter, which the company excluded from non-GAAP results. Source

Earlier plans management reported on

  • Not stated: The joint venture described as pending in the prior release closed on October 5, 2026, with SES businesses contributed to it.
  • Not stated: Management referred to enhancing 2026 guidance for a third consecutive quarter, while the revenue range was lowered in the same release. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.